Analyst Price Targets — TVRD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:23 am | — | Barclays | $3.00 | $3.39 | TheFly | Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays |
| October 13, 2025 8:14 pm | — | Barclays | $5.00 | $6.69 | TheFly | Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays |
| October 13, 2025 2:09 pm | Yasmeen Rahimi | Piper Sandler | $4.00 | $6.54 | TheFly | Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler |
| October 13, 2025 9:26 am | Etzer Darout | Barclays | $61.00 | $41.60 | TheFly | Tvardi Therapeutics initiated with an Overweight at Barclays |
| June 12, 2025 9:04 am | Yasmeen Rahimi | Piper Sandler | $78.00 | $26.11 | TheFly | Tvardi Therapeutics initiated with an Overweight at Piper Sandler |
Latest News for TVRD
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in…
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage…
Shares of Tvardi Therapeutics, Inc. (NASDAQ: TVRD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, three have given a buy
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVRD.
U.S. House Trading
No House trades found for TVRD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.